ArticleJournal of ovarian research2026
Role and mechanism of palmitic acid-regulated palmitoylation modification of SEC63 protein during endoplasmic reticulum stress in human ovarian granulosa tumor cells (KGN).
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo investigate the role and mechanism of palmitic acid (PA)-regulated palmitoylation modification of SEC63 protein during endoplasmic reticulum (ER) stress in human ovarian granulosa tumor cells (KGN).
methodsSerum samples were collected from 22 patients with polycystic ovary syndrome (PCOS) and 20 control subjects undergoing in vitro fertilization. Metabolomic analysis was performed to quantify serum fatty acid levels. KGN cells were treated with PA (0-400 µM) to assess cytotoxicity, ER stress, oxidative stress (OS), mitochondrial function, and apoptosis. Protective effects of lipoic acid (10 µM) and the ER stress inhibitor 4-phenylbutyric acid (4-PBA, 10 µM) were evaluated. Palmitoylation-modified proteomics and bioinformatics analyses were used to identify key proteins and pathways. A PCOS mouse model was established via dehydroepiandrosterone (DHEA) injection, and PA (100 mg/kg/d) was administered intraperitoneally for 21 days. Ovarian morphology, hormone levels, ER stress, and OS markers were analyzed.
resultsPA levels were significantly elevated in PCOS patients. In KGN cells, PA induced ER stress (upregulation of CHOP, GRP78, ATF6), OS (increased ROS, MDA, O₂•⁻; decreased antioxidant enzymes), mitochondrial dysfunction (reduced ATP, MMP), and apoptosis. Lipoic acid and 4-PBA ameliorated these effects. Proteomics identified SEC63 as a key palmitoylation-modified protein involved in ER stress. Mutation of SEC63 palmitoylation sites reduced ER stress and OS markers. Compared to the PA+SEC63-Flag group, the SEC63-C490 mutation led to a significant downregulation of GRP78 protein expression by approximately 70%. Furthermore, we also observed an downregulation of approximately 60% and 50% in the expression of two other key endoplasmic reticulum stress markers, CHOP and ATF6, respectively.In PA-treated mice, ovarian morphology showed polycystic characteristics, hormone levels (testosterone, E₂, P₄, LH, FSH) were dysregulated, and ER stress/OS markers were elevated.
conclusionPA induces ER stress and OS in KGN cells and mouse ovarian tissue via palmitoylation modification of SEC63, contributing to PCOS pathogenesis. Lipoic acid and SEC63 modulation may offer therapeutic potential for mitigating PA-induced ovarian dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.